Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Next Previous
Trial Profile

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rupitasertib (Primary) ; Elacestrant; Tamoxifen; Trastuzumab
  • Indications HER2 negative breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono

Most Recent Events

  • 22 Apr 2024 Data from this study were published in the Journal of Hematology & Oncology.
  • 19 Apr 2023 Results (n=20) assessing the exploratory correlative analyses in ER+ HER2-negative metastatic breast cancer patients in addition to nonclinical experiments to evaluate its role in the CDK4/6 and endocrine therapy (ET) resistant setting, presented at the 114th Annual Meeting of the American Association for Cancer Research.
  • 06 Apr 2023 According to Diaccurate Media Release, DIACC3010, expectedto enter phase 2/3 clinical trial in refractory ER positive and HER negative Metastatic breast cancer and phase 1 trial in glioblastoma multiforme.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top